VCEL - Vericel Corporation
| Previous Close | 10.95 |
| Open | 10.95 |
| Bid | 10.50 x 4000 |
| Ask | 11.30 x 900 |
| Day's Range | 10.15 - 11.00 |
| 52 Week Range | 2.95 - 14.75 |
| Volume | 6,402,299 |
| Avg. Volume | 1,122,619 |
| Market Cap | 466.744M |
| Beta | 4.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.87 |
- Simply Wall St.•5 days ago
When Will Vericel Corporation (NASDAQ:VCEL) Turn A Profit?
Vericel Corporation’s (NASDAQ:VCEL): Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. With the latestRead More...
- GlobeNewswire•20 days ago
Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
Leerink Partners acted as the lead bookrunner for the offering. BTIG, LLC also acted as a bookrunner. Ladenburg Thalmann acted as co-manager. The securities described above were offered by Vericel pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities Exchange Commission (SEC) on June 29, 2015 and declared effective by the SEC on July 15, 2015. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement for the offering was filed with the SEC on June 1, 2018, and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting Leerink Partners LLC, c/o Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 6132 or by contacting BTIG, LLC at 825 Third Avenue, 6th Floor, New York, NY, 10022, or by telephone at (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.
- ACCESSWIRE•20 days ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.
- GlobeNewswire•24 days ago
Vericel Corporation Prices $65 Million Public Offering of Common Stock
CAMBRIDGE, Mass., May 31, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten ...
- Thomson Reuters StreetEvents•25 days ago
Edited Transcript of VCEL earnings conference call or presentation 8-May-18 12:30pm GMT
Q1 2018 Vericel Corp Earnings Call
- GlobeNewswire•26 days ago
Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 30, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject ...
- GlobeNewswire•last month
Vericel to Present at the Jefferies 2018 Global Healthcare Conference
CAMBRIDGE, Mass., May 25, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will ...
- Yahoo Finance•last month
What this year's top fund managers are doing to smoke the competition
As big names have treaded water, the best performing funds have feasted in market famine thanks to little-known healthcare and technology companies.
Yahoo Finance•2 months agoAmerica's top fund is run by a father-son duo from the shores of Lake Minnetonka
The best performing mutual fund so far this year - beating the S&P 500 by more than 20% - is run by a small-town duo of father and son.
- GlobeNewswire•2 months ago
Vericel Reports First Quarter 2018 Financial Results
Record First Quarter Revenues of $18.0 Million. Conference Call Today at 8:30am Eastern Time. CAMBRIDGE, Mass., May 08, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine ...
- GlobeNewswire•2 months ago
Recent Analysis Shows American Vanguard, Magellan Midstream Partners, Diamondback Energy, Vericel, Air Lease, and Century Communities Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Investopedia•2 months ago
Vericel Stock Looks to Break Out From Prior Highs
Vericel shares are retesting their prior highs following positive analyst commentary.
- MarketWatch•2 months ago
Harry Boxer’s five biotech stocks to watch
In focus: uniQure, Regenxbio, Tandem Diabetes Care, Vericel and Xencor.
- Zacks•2 months ago
Will Vericel (VCEL) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Vericel Corporation (VCEL).
- GlobeNewswire•2 months ago
Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 10, 2018-- Vericel Corporation, a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...
- Investopedia•3 months ago
3 Biotech Stocks Hitting New Highs
Small- and mid-cap biotech stocks have displayed usual first quarter resilience, setting the stage for second quarter upside.
- ACCESSWIRE•3 months ago
Blog Exposure - Vericel Announced Publication of Results from Phase-3 SUMMIT Extension Study
Stock Monitor: BioSpecifics Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on Vericel Corp. (NASDAQ: VCEL ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of VCEL earnings conference call or presentation 5-Mar-18 1:30pm GMT
Q4 2017 Vericel Corp Earnings Call
- ACCESSWIRE•4 months ago
Today’s Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / U.S. markets rallied Monday, with the Dow breaking a streak of 4 consecutive losses, as concerns over a potential trade war eased. The Dow Jones Industrial Average ...
